BioSpace News Archive

Biotech Bay

McKesson Reaffirms Fiscal 2019 Guidance and Provides Preliminary Guidance for the First Quarter

The company also anticipates Adjusted Earnings per diluted share of approximately $2.85 to $2.95 for the first quarter of Fiscal 2019.

June 28, 2018
·
5 min read
Pharm Country

Hudson Regional Hospital Announces Acquisition Of Advanced da Vinci Robotic Surgical System

Hudson Regional Hospital’s procurement of the da Vinci XI robotic surgical system is the most recent example of the hospital’s new ownership’s commitment towards investing in advanced technologies that will greatly benefit the community

June 28, 2018
·
3 min read
Genetown

Arsanis Provides Update Following Completion of Planned Interim Analysis of Phase 2 Clinical Trial of ASN100

Arsanis, Inc. (NASDAQ:ASNS), today announced the discontinuation of its Phase 2 clinical trial of ASN100.

June 28, 2018
·
5 min read
Drug Development

Akebia and Keryx Merge to Become Leader in Therapies for Chronic Kidney Disease

Shares of Akebia Therapeutics are up more than 10 percent in premarket trading after the company announced it struck a merger agreement with Keryx Biopharmaceuticals, Inc. to create a company expected to be a leader in the development of renal disease therapies.

June 28, 2018
·
2 min read
·
Alex Keown
Genetown

Platelet BioGenesis Receives $3.5 Million Grant from Department of Defense

Platelet Biogenesis (PBG) was awarded a two-year, $3.5 million grant from the U.S. Department of Defense (DoD). The funds are to support the company’s proprietary bioreactor to produce therapeutic amounts of platelets.

June 28, 2018
·
2 min read
·
Mark Terry
FDA

Array Snags FDA Approval for BRAF-Mutant Metastatic Melanoma Combination Treatment

Array BioPharma, Inc. secured approval for its combination treatment for BRAF-mutant metastatic melanoma.

June 28, 2018
·
2 min read
·
Alex Keown
Deals

Takeda Shareholders Group Opposed to Shire Merger Lose Bid

A group of Takeda Pharmaceutical shareholders’ bid to halt the acquisition of Dublin-based Shire failed to gain traction.

June 28, 2018
·
2 min read
·
Mark Terry
Drug Development

Lilly’s Taltz Hit Primary and Secondary Endpoints in Ankylosing Spondylitis Trial

Eli Lilly and Company announced the results of its COAST-W Phase III clinical trial of Taltz (ixekizumab) to treat Ankylosing Spondylitis (AS). The trial met both primary and major secondary endpoints.

June 28, 2018
·
2 min read
·
Mark Terry
FDA

Sprout Relaunches Female Sex Drive Pill Addyi at Half the Price Charged Under Valeant

After failing to gain market share under the umbrella of Valeant Pharmaceuticals, Addyi is getting a relaunch at half the price.

June 28, 2018
·
2 min read
·
Alex Keown
Drug Development

BrainStorm Expands Leadership Team on Heels of Right-to-Try Controversy

The senior leadership team at Israel-based BrainStorm Cell Therapeutics, Inc. has changed with the appointments of two seasoned industry veterans Joseph Petroziello and Susan Ward.

June 28, 2018
·
2 min read
·
Alex Keown